Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Sibasish Mohanty"'
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
m6A RNA methylation, which serves as a critical regulator of transcript expression, has gathered tremendous scientific interest in recent years. From RNA processing to nuclear export, RNA translation to decay, m6A modification has been studied to aff
Externí odkaz:
https://doaj.org/article/953dcf39738745a59f942897c86a6450
Autor:
Pallavi Mohapatra, Omprakash Shriwas, Sibasish Mohanty, Arup Ghosh, Shuchi Smita, Sandeep Rai Kaushik, Rakesh Arya, Rachna Rath, Saroj Kumar Das Majumdar, Dillip Kumar Muduly, Sunil K. Raghav, Ranjan K. Nanda, Rupesh Dash
Publikováno v:
JCI Insight, Vol 6, Iss 4 (2021)
Rewiring tumor cells to undergo drug-induced apoptosis is a promising way to overcome chemoresistance. Therefore, identifying causative factors for chemoresistance is of high importance. Unbiased global proteome profiling of sensitive, early, and lat
Externí odkaz:
https://doaj.org/article/ff7cbbff47654536897a562f50eb8bc2
Autor:
Sibasish Mohanty, Pallavi Mohapatra, Omprakash Shriwas, Shamima Azma Ansari, Manashi Priyadarshini, Swatismita Priyadarsini, Rachna Rath, Mahesh Sultania, Saroj Kumar Das Majumdar, Rajeeb Kumar Swain, Rupesh Dash
Publikováno v:
Oncogene. 41:4929-4940
Cisplatin, 5FU and docetaxel (TPF) are the most common chemotherapy regimen used for advanced OSCC. However, many cancer patients experience relapse, continued tumor growth, and spread due to drug resistance, which leads to treatment failure and meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af366c03f4d41b141fa4a41edf6089c9
https://doi.org/10.1038/s41388-022-02475-8
https://doi.org/10.1038/s41388-022-02475-8
Autor:
Pallavi Mohapatra, Sibasish Mohanty, Shamima Azma Ansari, Omprakash Shriwas, Arup Ghosh, Rachna Rath, Saroj Kumar Das Majumdar, Rajeeb K. Swain, Sunil K. Raghav, Rupesh Dash
Publikováno v:
FASEB journal : official publication of the Federation of American Societies for Experimental BiologyREFERENCES. 36(10)
CMTM6, a type 3 transmembrane protein, is known to stabilize the expression of programmed cell death ligand 1 (PD-L1) and hence facilitates the immune evasion of tumor cells. Recently, we demonstrated that CMTM6 is a major driver of cisplatin resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbb4828888beddf30ff4863b0c84ac9a
https://pubmed.ncbi.nlm.nih.gov/36165231
https://pubmed.ncbi.nlm.nih.gov/36165231
Autor:
Pallavi Mohapatra, Sibasish Mohanty, Shamima Azma Ansari, Omprakash Shriwas, Arup Ghosh, Rachna Rath, Saroj Kumar Das Majumdar, Rajeeb K Swain, Sunil K Raghav, Rupesh Dash
CMTM6, a type 3 transmembrane protein, is known to stabilize the expression of programmed cell death ligand 1 (PD-L1) and hence facilitates the immune evasion of tumor cells. Recently, we demonstrated that CMTM6 is a major driver of cisplatin resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab7940b6ce3be7087907b983f3fe19e5
https://doi.org/10.1101/2022.04.08.487634
https://doi.org/10.1101/2022.04.08.487634
Autor:
Shuchi Smita, Sandeep Rai Kaushik, Rakesh Arya, Arup Kumar Ghosh, Rupesh Dash, Pallavi Mohapatra, Rachna Rath, Omprakash Shriwas, Saroj Kumar Das Majumdar, Ranjan Kumar Nanda, Dillip Kumar Muduly, Sibasish Mohanty, Sunil K. Raghav
Publikováno v:
JCI Insight, Vol 6, Iss 4 (2021)
JCI Insight
JCI Insight
Rewiring tumor cells to undergo drug-induced apoptosis is a promising way to overcome chemoresistance. Therefore, identifying causative factors for chemoresistance is of high importance. Unbiased global proteome profiling of sensitive, early, and lat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b61f357cbe024d315d0a5389590991c6
https://doaj.org/article/ff7cbbff47654536897a562f50eb8bc2
https://doaj.org/article/ff7cbbff47654536897a562f50eb8bc2
Autor:
Rupesh Dash, Saroj Kumar Das Majumdar, Falak Pahwa, Anshuman Dixit, Sandeep Rai Kaushik, Dillip Kumar Muduly, Punit Prasad, Omprakash Shriwas, Ranjan Kumar Nanda, Sugandh Kumar, Rakesh Arya, Krushna Chandra Murmu, Rachna Rath, Pallavi Mohapatra, Sibasish Mohanty
Publikováno v:
Br J Cancer
Background Chemoresistance is one of the major factors for treatment failure in OSCC. Identifying key resistance triggering molecules will be useful strategy for developing novel treatment methods. Methods To identify the causative factors of chemore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a9cd5f66b70d128f5dec6e5de5abd72
https://pubmed.ncbi.nlm.nih.gov/33963301
https://pubmed.ncbi.nlm.nih.gov/33963301
Autor:
Mukund Chandra Thakur, Rachna Rath, Saroj Kumar Das Majumdar, Rupesh Dash, Sandeep Rai Kaushik, Sibasish Mohanty, Omprakash Shriwas, Sugandh Kumar, Dillip Kumar Muduly, Falak Pahwa, Ranjan Kumar Nanda, Rakesh Arya
Cisplatin-based chemotherapy still remains as one of the primary treatment modalities for OSCC. Several OSCC patients experience relapse owing to development of chemoresistance. To identify key resistance triggering molecules, we performed global pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::689e38c7ea783e50ecde6acd02a7ed20
https://doi.org/10.1101/2020.03.18.998070
https://doi.org/10.1101/2020.03.18.998070
Autor:
Saroj Kumar Das Majumdar, Sandeep Rai Kaushik, Rupesh Dash, Pallavi Mohapatra, Rakesh K. Arya, Ranjan Kumar Nanda, Sibasish Mohanty, Rachna Rath, Omprakash Shriwas, Dillip Kumar Muduly
Chemoresistance is one of the important factors for treatment failure in OSCC, which can culminate in progressive tumor growth and metastatic spread. Rewiring tumor cells to undergo drug-induced apoptosis is a promising way to overcome chemoresistanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::867d02c21438ccf75f42cbfa2f04fb4e
https://doi.org/10.1101/2020.03.18.993774
https://doi.org/10.1101/2020.03.18.993774
Publikováno v:
Biomaterials for 3D Tumor Modeling ISBN: 9780128181287
Despite of having the initial positive responses of chemotherapy, many cancer patients experience relapse with continued tumor growth and metastasis due to development of drug resistance. Chemoresistance is one of the main reasons for treatment failu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::761398d84b44264bf4e514c49f7fd160
https://doi.org/10.1016/b978-0-12-818128-7.00020-4
https://doi.org/10.1016/b978-0-12-818128-7.00020-4